Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosapramine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mosapramine is an atypical antipsychotic drug primarily used in Japan for the treatment of schizophrenia. It acts as a potent dopamine antagonist with high affinity for dopamine D2, D3, and D4 receptors and moderate affinity for 5-HT2 (serotonin) receptors. Mosapramine belongs to the chemical class of dibenzazepines and is considered a second-generation (atypical) antipsychotic. The drug is administered orally.
- Brand names
- Cremin
- Other names
- clospipraminemosapramine dihydrochloride
02
Targets
DRD3 (Dopamine receptor D3)HTR2A (Serotonin receptor 5-HT2A)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on mosapramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosapramine.